May 10, 2025 06:00 AM EDT
Weekly

Makary names Vinay Prasad CBER chief; Q1 earn­ings re­port; More on “Most Fa­vored Na­tions"; and more

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

No­vo Nordisk trims growth fore­cast as GLP-1 com­pounder ban yet to go live

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times